Contact Center Industry News

TMCNet:  Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent

[August 29, 2014]

Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced Hematologic Malignancies

BOSTON --(Business Wire)--

Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM's anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS). The trial is carried out at the University of Texas MD Anderson Cancer Center (MD Anderson) with Guillermo Garcia-Manero, M.D., Professor, as the Principal Investigator. Prof. Garcia-Manero is a world-renowned expert in advanced hematologic malignancies, especially MDS.

MDS is a type of hematologic malignancy, in which the disorder of blood-forming "hematopoietic stem cells" causes inefficient production of blood cells triggering cytoenia. It is also a refractory disease for some patients with poor prognosis, progressing to acute myeloid leukemia. The U.S. incidence of MDS is 60,000 cases per year, most of them in the senior age group. FF-10501 is expected to inhibit the growth of hematological cancer cells and promote their differentiation to normally functioning cells.

MD Anderson is one of the world's top general cancer centers with over 10,000 patients enrolled in therapeutic clinical trials each year and approximately 20,000 employees. BSC is able to utilize the world's top-level clinical testing functions available at the MD Anderson under a Strategic Alliance Agreement to carry out Phase 1 and early Phase 2 clinical trials to gain preliminary safety information and clinical activity in cancer patients. "We are very excited to be collaborating with FPHU and BSC on this important clinical trial in patients with advanced hematologic malignancies," said Prof. Guillermo Garcia-Manero. "This drug will provide another alternative for patients who have failed conventional chemotherapeutic approaches, and we are pleased to be furthering this research at our institution."

This clinical trial is the first example of a BSC and FPHU collaboration, whereby BSC optimizes and executes the global strategy of FPHU Oncology drug development programs. Utilizing Boston Strategics' internal oncology development expertise and its ability to leverage the "True" Open Innovation™ network to collaborate with the best resources around the world, BSC will be able to deliver to FPHU more efficient and superior outcomes to cancer patients worldwide.

"This is a important milestone in BSC and FPHU partnership to develop a new pharmaceutical R&D platform for FPHU, which looks for an innovative and efficient way for global development of FUJIFILM's unique oncology pipeline", says Eita Kitayama, President of Boston Strategics. "Both companies are fully committed to deliver breakthrough therapies using innovative approaches to achieve industry benchmark-beating timelines, quality, and financial investments for important novel anti-cancer agents."

About Boston Strategics Corporation (BSC):

BSC is an integrated drug R&D company with experience in developing, managing and optimizing global drug development programs from late discovery, through translational research, first-in-man proof-of-concept studies. Its mission is to continuously improve patient health care by changing the drug R&D paradigm using "True" Open Innovation™ platform.

[ Back To Cloud Contact Center's Homepage ]


Featured Resources

Featured Report
Millennial Research on Customer Service Expectations

Millennial Research on Customer Service Expectations

The "why" behind this research is simple: our clients recognize that different generations bring different expectations, varied communication preferences and new customer service patterns to the customer experience...
Featured Report
Optimizing the Customer Experience through Cloud Contact Centers

Optimizing the Customer Experience through Cloud Contact Centers

Adoption of cloud contact centers is on the rise. Findings from Aberdeen's January 2014 'Public Cloud vs. On-Premise: How to More Effectively Deploy a Cloud Center' study shows that 31% of contact centers are deployed in the cloud, and our related blog post highlights that companies anticipate their adoption of cloud technology to rise further throughout 2014...
Featured Report
Aberdeen report

Aberdeen Report: Cloud for Mid-Sized Contact Centers – What You Must Know

Cloud Technology is opening new doors for many businesses. However, it does so only when it's combined with the use of best practices and key technology enablers. This document highlights the adoption of cloud technology by mid-size contact centers and illustrates the reasons driving their investments...
Featured Whitepaper
Aberdeen report

Seven Critical Capabilities to Demand From Your Cloud Contact Center Provider

To deliver a world-class customer experience, your contact center must be flexible and reliable, while providing all the tools agents and supervisors need to manage their workflows. Here are seven critical capabilities to look for when deploying a contact center in the cloud...
Featured Webinar

Contact Center Economics and the Cloud

Together, Bob and Drew will help you understand the economic value of upgrading technology, important business and financial considerations, and how to compare total cost of ownership of a premises vs. cloud or hosted solution. Watch the webinar on-demand now...
Featured Datasheet
Zipwire Cloud Contact Center

Zipwire Cloud Contact Center

The appeal of moving services to the cloud is obvious. Cloud services offer reliability and robust feature sets without the need to implement or maintain complex contact center infrastructure. The Zipwire™ cloud-based contact center allows businesses to leverage the flexibility and cost savings of cloud architecture while offering a seamless, first-class customer experience...